. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 Feb 12;175(2):297–303. doi: 10.1007/s10549-019-05158-3

Table 3.

Effects of UG2B17 and AI treatment on Changes in BMD and BTM

		Change in Bone Mineral Density between baseline and 24 months (T-score)				Change in Bone Turnover Markers between baseline and 3 months
		Hip		Spine		Serum BAP		Urine NTx
		mean (std)	p-value	mean (std)	p-value	mean (std)	p-value	mean (std)	p-value
Aromatase Inhibitor	Letrozole	−0.68 (2.85)	0.03	−0.27 (0.49	0.03	0.10 (5.62)	0.72	−6.62 (345.11)	0.02
Aromatase Inhibitor	Exemestane	−0.17 (1.12)	0.03	−0.17 (0.53)	0.03	−0.05 (4.82)	0.72	75.90 (350.39)	0.02
UGT2B17 Genotype	1/1	−0.43 (2.18)	0.24	−0.20 (0.56)	0.10	0.35 (4.25)	0.21	47.90 (319.30)	0.25
	1/2	−0.27 (0.40)		−0.16 (0.46)		−0.32 (6.30)		37.62 (395.48)
	2/2	−1.32 (5.30)		−0.30 (0.50)		0.12 (3.79)		−24.52 (270.96)

Bold denotes associations significant at the p<0.05 level.